Ticker	Volume	Price	Price Delta
DJIA	15,303.10	+8.60	0.06%
S&P 500	1,649.60	-0.91	-0.06%
Nasdaq	3,459.14	-0.27	-0.01%

Ticker

Volume

Price

Price Delta

DJIA

15,303.10

+8.60

0.06%

S&P 500

1,649.60

-0.91

-0.06%

Nasdaq

3,459.14

-0.27

-0.01%

Ticker	Volume	Price	Price Delta
STOXX 50	2,764.29	-12.49	-0.45%
FTSE 100	6,654.34	-42.45	-0.63%
DAX	8,305.32	-46.66	-0.56%

Ticker

Volume

Price

Price Delta

STOXX 50

2,764.29

-12.49

-0.45%

FTSE 100

6,654.34

-42.45

-0.63%

DAX

8,305.32

-46.66

-0.56%

Ticker	Volume	Price	Price Delta
Nikkei	14,612.50	+128.47	0.89%
Hang Seng	22,618.70	-51.01	-0.23%
S&P/ASX 200	4,983.50	-78.95	-1.56%

Ticker

Volume

Price

Price Delta

Nikkei

14,612.50

+128.47

0.89%

Hang Seng

22,618.70

-51.01

-0.23%

S&P/ASX 200

4,983.50

-78.95

-1.56%

Newron Declines 12% in Zurich Trading as Talks Over Sale to Santhera End

By Phil Serafino - 2011-02-03T08:05:53Z

Newron Pharmaceuticals SpA, the Italian drugmaker developing a Parkinson’s disease treatment with Merck KGaA, fell in Zurich trading after saying talks with Santhera Pharmaceuticals Holding AG have ended.

The stock fell 80 centimes, or 12 percent, to 5.90 Swiss francs at 9:05 a.m.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

More News:

Health Care

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.